# Natural Alternatives International Inc: financial statements, quarterly

NAII · Nasdaq · CIK 787253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/naii.md) · [Financials](/companies/naii/financials.md) · [Filings](/companies/naii/filings.md) · [Insiders](/companies/naii/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/naii/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [34.0](/filings/0001437749-24-034914.md) | [25.2](/filings/0001437749-25-004002.md) | [25.1](/filings/0001437749-25-016911.md) | [29.5 d](/filings/0001437749-25-029731.md) | [33.2](/filings/0001437749-25-034473.md) | [34.1](/filings/0001437749-26-004118.md) | [28.8](/filings/0001437749-26-017684.md) | [33.9 d](/filings/0001437749-26-031343.md) | [37.7](/filings/0001437749-25-034473.md) | [34.8](/filings/0001437749-26-004118.md) | [35.5](/filings/0001437749-26-017684.md) | [34.5 d](/filings/0001437749-26-031343.md) |
| Cost of revenue | $m | [30.8](/filings/0001437749-24-034914.md) | [24.8](/filings/0001437749-25-004002.md) | [23.2](/filings/0001437749-25-016911.md) | [28.1 d](/filings/0001437749-25-029731.md) | [30.9](/filings/0001437749-25-034473.md) | [32.4](/filings/0001437749-26-004118.md) | [26.9](/filings/0001437749-26-017684.md) | [30.3 d](/filings/0001437749-26-031343.md) | [33.3](/filings/0001437749-25-034473.md) | [32.3](/filings/0001437749-26-004118.md) | [35.1](/filings/0001437749-26-017684.md) | [32.8 d](/filings/0001437749-26-031343.md) |
| Gross profit | $m | [3.1](/filings/0001437749-24-034914.md) | [0.4](/filings/0001437749-25-004002.md) | [1.9](/filings/0001437749-25-016911.md) | [1.4 d](/filings/0001437749-25-029731.md) | [2.3](/filings/0001437749-25-034473.md) | [1.7](/filings/0001437749-26-004118.md) | [1.8](/filings/0001437749-26-017684.md) | [3.5 d](/filings/0001437749-26-031343.md) | [4.4](/filings/0001437749-25-034473.md) | [2.5](/filings/0001437749-26-004118.md) | [0.4](/filings/0001437749-26-017684.md) | [1.7 d](/filings/0001437749-26-031343.md) |
| Selling, general and administrative | $m | [3.7](/filings/0001437749-24-034914.md) | [3.9](/filings/0001437749-25-004002.md) | [3.9](/filings/0001437749-25-016911.md) | not reported | [4.1](/filings/0001437749-25-034473.md) | [4.4](/filings/0001437749-26-004118.md) | [3.9](/filings/0001437749-26-017684.md) | not reported | [4.1](/filings/0001437749-25-034473.md) | [4.3](/filings/0001437749-26-004118.md) | [4.4](/filings/0001437749-26-017684.md) | not reported |
| Operating income | $m | [(0.5)](/filings/0001437749-24-034914.md) | [(3.5)](/filings/0001437749-24-003906.md) | [(2.0)](/filings/0001437749-25-016911.md) | [(2.5) d](/filings/0001437749-25-029731.md) | [(1.8)](/filings/0001437749-25-034473.md) | [(2.8)](/filings/0001437749-26-004118.md) | [(2.1)](/filings/0001437749-26-017684.md) | [(1.9) d](/filings/0001437749-26-031343.md) | [0.3](/filings/0001437749-25-034473.md) | [(1.8)](/filings/0001437749-26-004118.md) | [(4.0)](/filings/0001437749-26-017684.md) | [(13.2) d](/filings/0001437749-26-031343.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.2)](/filings/0001437749-24-034914.md) | [(0.8)](/filings/0001437749-25-004002.md) | [(0.4)](/filings/0001437749-25-016911.md) | [(0.9) d](/filings/0001437749-25-029731.md) | [(0.4)](/filings/0001437749-25-034473.md) | [(0.7)](/filings/0001437749-26-004118.md) | [(0.5)](/filings/0001437749-26-017684.md) | [4.4 d](/filings/0001437749-26-031343.md) | [0.1](/filings/0001437749-25-034473.md) | [0.2](/filings/0001437749-26-004118.md) | [0.1](/filings/0001437749-26-017684.md) | [0.0 d](/filings/0001437749-26-031343.md) |
| Net income | $m | [(0.7)](/filings/0001437749-24-034914.md) | [(3.1)](/filings/0001437749-25-004002.md) | [(1.6)](/filings/0001437749-25-016911.md) | [(1.9) d](/filings/0001437749-25-029731.md) | [(2.0)](/filings/0001437749-25-034473.md) | [(2.2)](/filings/0001437749-26-004118.md) | [(2.2)](/filings/0001437749-26-017684.md) | [(7.2) d](/filings/0001437749-26-031343.md) | [(0.3)](/filings/0001437749-25-034473.md) | [(2.6)](/filings/0001437749-26-004118.md) | [(4.3)](/filings/0001437749-26-017684.md) | [(13.5) d](/filings/0001437749-26-031343.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001437749-24-034914.md) | [(0.52)](/filings/0001437749-25-004002.md) | [(0.27)](/filings/0001437749-25-016911.md) | not reported | [(0.33)](/filings/0001437749-25-034473.md) | [(0.37)](/filings/0001437749-26-004118.md) | [(0.37)](/filings/0001437749-26-017684.md) | not reported | [(0.05)](/filings/0001437749-25-034473.md) | [(0.42)](/filings/0001437749-26-004118.md) | [(0.72)](/filings/0001437749-26-017684.md) | not reported |
| Basic EPS | $ per share | [(0.12)](/filings/0001437749-24-034914.md) | [(0.52)](/filings/0001437749-25-004002.md) | [(0.27)](/filings/0001437749-25-016911.md) | not reported | [(0.33)](/filings/0001437749-25-034473.md) | [(0.37)](/filings/0001437749-26-004118.md) | [(0.37)](/filings/0001437749-26-017684.md) | not reported | [(0.05)](/filings/0001437749-25-034473.md) | [(0.42)](/filings/0001437749-26-004118.md) | [(0.72)](/filings/0001437749-26-017684.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.7](/filings/0001437749-23-031262.md) | [16.6](/filings/0001437749-24-003906.md) | [12.4](/filings/0001437749-24-016627.md) | [12.0](/filings/0001437749-25-029731.md) | [10.2](/filings/0001437749-24-034914.md) | [8.7](/filings/0001437749-25-004002.md) | [10.6](/filings/0001437749-25-016911.md) | [12.3](/filings/0001437749-26-031343.md) | [7.7](/filings/0001437749-25-034473.md) | [3.8](/filings/0001437749-26-004118.md) | [9.2](/filings/0001437749-26-017684.md) | [7.4](/filings/0001437749-26-031343.md) |
| Current assets | $m | [57.8](/filings/0001437749-23-031262.md) | [54.4](/filings/0001437749-24-003906.md) | [54.4](/filings/0001437749-24-016627.md) | [61.6](/filings/0001437749-25-029731.md) | [62.5](/filings/0001437749-24-034914.md) | [58.5](/filings/0001437749-25-004002.md) | [58.5](/filings/0001437749-25-016911.md) | [59.3](/filings/0001437749-26-031343.md) | [65.1](/filings/0001437749-25-034473.md) | [61.5](/filings/0001437749-26-004118.md) | [64.0](/filings/0001437749-26-017684.md) | [65.4](/filings/0001437749-26-031343.md) |
| Total assets | $m | [160](/filings/0001437749-23-031262.md) | [156](/filings/0001437749-24-003906.md) | [153](/filings/0001437749-24-016627.md) | [162](/filings/0001437749-25-029731.md) | [161](/filings/0001437749-24-034914.md) | [156](/filings/0001437749-25-004002.md) | [155](/filings/0001437749-25-016911.md) | [152](/filings/0001437749-26-031343.md) | [157](/filings/0001437749-25-034473.md) | [153](/filings/0001437749-26-004118.md) | [155](/filings/0001437749-26-017684.md) | [126](/filings/0001437749-26-031343.md) |
| Current liabilities | $m | [15.4](/filings/0001437749-23-031262.md) | [13.4](/filings/0001437749-24-003906.md) | [13.6](/filings/0001437749-24-016627.md) | [23.5](/filings/0001437749-25-029731.md) | [24.4](/filings/0001437749-24-034914.md) | [21.6](/filings/0001437749-25-004002.md) | [23.3](/filings/0001437749-25-016911.md) | [28.8](/filings/0001437749-26-031343.md) | [33.9](/filings/0001437749-25-034473.md) | [32.8](/filings/0001437749-26-004118.md) | [39.1](/filings/0001437749-26-017684.md) | [37.7](/filings/0001437749-26-031343.md) |
| Total liabilities | $m | [71.4](/filings/0001437749-23-031262.md) | [70.3](/filings/0001437749-24-003906.md) | [69.1](/filings/0001437749-24-016627.md) | [79.7](/filings/0001437749-25-029731.md) | [81.1](/filings/0001437749-24-034914.md) | [77.0](/filings/0001437749-25-004002.md) | [78.3](/filings/0001437749-25-016911.md) | [83.5](/filings/0001437749-26-031343.md) | [87.9](/filings/0001437749-25-034473.md) | [86.3](/filings/0001437749-26-004118.md) | [91.8](/filings/0001437749-26-017684.md) | [76.5](/filings/0001437749-26-031343.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [88.8](/filings/0001437749-25-004002.md) | [85.5](/filings/0001437749-25-016911.md) | [84.1](/filings/0001437749-25-016911.md) | [82.6](/filings/0001437749-26-031343.md) | [80.2](/filings/0001437749-26-004118.md) | [79.1](/filings/0001437749-26-017684.md) | [76.6](/filings/0001437749-26-017684.md) | [68.4](/filings/0001437749-26-031343.md) | [69.0](/filings/0001437749-26-004118.md) | [67.0](/filings/0001437749-26-017684.md) | [63.1](/filings/0001437749-26-017684.md) | [50.0](/filings/0001437749-26-031343.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [4,496](/filings/0001437749-24-034914.md) | [348 d](/filings/0001437749-25-004002.md) | [(3,624) d](/filings/0001437749-25-016911.md) | [(2,717) d](/filings/0001437749-25-029731.md) | [(3,443)](/filings/0001437749-25-034473.md) | [37.0 d](/filings/0001437749-26-004118.md) | [5,993 d](/filings/0001437749-26-017684.md) | [3,345 d](/filings/0001437749-26-031343.md) | [(4,023)](/filings/0001437749-25-034473.md) | [(6,330) d](/filings/0001437749-26-004118.md) | [2,503 d](/filings/0001437749-26-017684.md) | [(1,066) d](/filings/0001437749-26-031343.md) |
| Capital expenditure | $k | [1,278](/filings/0001437749-24-034914.md) | [429 d](/filings/0001437749-25-004002.md) | [276 d](/filings/0001437749-25-016911.md) | [1,034 d](/filings/0001437749-25-029731.md) | [301](/filings/0001437749-25-034473.md) | [1,056 d](/filings/0001437749-26-004118.md) | [802 d](/filings/0001437749-26-017684.md) | [1,455 d](/filings/0001437749-26-031343.md) | [1,030](/filings/0001437749-25-034473.md) | [934 d](/filings/0001437749-26-004118.md) | [1,100 d](/filings/0001437749-26-017684.md) | [637 d](/filings/0001437749-26-031343.md) |
| Share repurchases | $k | [0.0](/filings/0001437749-24-034914.md) | [0.0 d](/filings/0001437749-25-004002.md) | [217 d](/filings/0001437749-25-016911.md) | [4.0 d](/filings/0001437749-25-029731.md) | [8.0](/filings/0001437749-25-034473.md) | [0.0 d](/filings/0001437749-26-004118.md) | [168 d](/filings/0001437749-26-017684.md) | [2.0 d](/filings/0001437749-26-031343.md) | [5.0](/filings/0001437749-25-034473.md) | [0.0 d](/filings/0001437749-26-004118.md) | [82.0 d](/filings/0001437749-26-017684.md) | [2.0 d](/filings/0001437749-26-031343.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | period not labelled (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,943](/filings/0001437749-23-031262.md) | [5,873](/filings/0001437749-24-003906.md) | [5,816](/filings/0001437749-24-016627.md) | [5,850](/filings/0001437749-24-034914.md) | [5,850](/filings/0001437749-25-004002.md) | [5,868](/filings/0001437749-25-016911.md) | [5,919](/filings/0001437749-25-034473.md) | [5,921](/filings/0001437749-26-004118.md) | [5,943](/filings/0001437749-26-017684.md) | [6,007](/filings/0001437749-25-034473.md) | [6,008](/filings/0001437749-26-004118.md) | [6,025](/filings/0001437749-26-017684.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,113,000 at 2026-09-28, from the cover of the [10-K filed 2026-09-28](/filings/0001437749-26-031343.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.